Hematology Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test (Blood Count, Platelet Function, Hemoglobin, Hematocrit), By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Hematology Diagnostics Market Growth & Trends
The global hematology diagnostics market size is expected treach USD 5.93 billion by 2030, according ta new report by Grand View Research, Inc. It is anticipated tregister a CAGR of 6.6% from 2025 t2030. Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected tpropel the market growth.
Automation of hematology diagnostics process have led treduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has alsled treduced administrative errors and overall costs of diagnostic tests. Thus, it is expected tboost growth of the hematology testing market in the forthcoming years.
Dominance of hematology analyzers can be attributed tthe presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can alsdetect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.
The advent of Point-Of-Care (PoC) hematology testing devices has led timproved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated tincrease the acceptability and accessibility of hematology testing which, in turn, is anticipated tpropel market growth.
Product recall and intense market competition leading tprice wars are anticipated thinder market growth. In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing tchemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.
Hematology Diagnostics Market Report Highlights
Hematology Diagnostics Market Growth & Trends
The global hematology diagnostics market size is expected treach USD 5.93 billion by 2030, according ta new report by Grand View Research, Inc. It is anticipated tregister a CAGR of 6.6% from 2025 t2030. Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected tpropel the market growth.
Automation of hematology diagnostics process have led treduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has alsled treduced administrative errors and overall costs of diagnostic tests. Thus, it is expected tboost growth of the hematology testing market in the forthcoming years.
Dominance of hematology analyzers can be attributed tthe presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can alsdetect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.
The advent of Point-Of-Care (PoC) hematology testing devices has led timproved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated tincrease the acceptability and accessibility of hematology testing which, in turn, is anticipated tpropel market growth.
Product recall and intense market competition leading tprice wars are anticipated thinder market growth. In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing tchemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.
Hematology Diagnostics Market Report Highlights
- The consumables segment dominated the market with a share of 66.0% in 2023 and is alsexpected twitness the fastest growth with a CAGR of 6.9% in the forecast period.
- The blood count segment captured the largest revenue share at 45.0 % in 2024. Organizations such as the American Cancer Society are rising awareness about diseases and chronic conditions such as Neutropenia, which are caused low WBC counts, propelling the population towards having frequent WBCs test.
- The hospital segment held the largest revenue share of 41.0% in 2024. This is attributable tgrowing hematology diagnostics demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, detecting illegal drug use, monitoring therapeutic drug levels, protein analysis, blood typing, thyroid function assessment, and detecting the presence of antibodies.
- North America hematology diagnostics market dominated the market and accounted for a 45.0 % share in 2024.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Test type
1.2.3. End-use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Test type outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. HEMATOLOGY DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of blood cancer
3.2.1.2. Technological advancements
3.2.1.3. Rising point-of-care (POC) hematological tests
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulations
3.2.2.2. High cost of product
3.3. Hematology Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. HEMATOLOGY DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Hematology Testing Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Instrument
4.4.1.1. Instrument Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Analyzers
4.4.1.2.1. Analyzers Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Flow cytometers
4.4.1.3.1. Flow cytometers Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Others
4.4.1.4.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Consumables
4.4.2.1. Consumables Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Reagents
4.4.2.2.1. Reagents Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Strains
4.4.2.3.1. Strains Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. HEMATOLOGY DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
5.1. Test type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Hematology Testing Market by Test type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Blood count
5.4.1.1. Blood count Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Platelet function
5.4.2.1. Platelet function Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hemoglobin
5.4.3.1. Hemoglobin Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Hematocrit
5.4.4.1. Hematocrit Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. HEMATOLOGY DIAGNOSTICS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Hematology Testing Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals
6.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic labs
6.4.2.1. Diagnostic labs Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. HEMATOLOGY DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. North America
7.5.2. U.S.
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Canada
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. Europe
7.6.2. UK
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Germany
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. France
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Italy
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Spain
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Norway
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive scenario
7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Sweden
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework
7.6.8.3. Competitive scenario
7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.9. Denmark
7.6.9.1. Key country dynamics
7.6.9.2. Regulatory framework
7.6.9.3. Competitive scenario
7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. China
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. India
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. Australia
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.7. Thailand
7.7.7.1. Key country dynamics
7.7.7.2. Regulatory framework
7.7.7.3. Competitive scenario
7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Latin America
7.8.2. Brazil
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. MEA
7.9.2. South Africa
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework
7.9.2.3. Competitive scenario
7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework
7.9.3.3. Competitive scenario
7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. UAE
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework
7.9.4.3. Competitive scenario
7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key country dynamics
7.9.5.2. Regulatory framework
7.9.5.3. Competitive scenario
7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Abbott
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Beckman coulter Inc,
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sysmex Corporation
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. F. Hoffman-La Roche Ltd.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Siemens Healthineers
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Nihon Kohden Corporation
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Bio-Rad laboratories
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Horiba Medical
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. EKF Diagnostics
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Test type
1.2.3. End-use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Test type outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. HEMATOLOGY DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of blood cancer
3.2.1.2. Technological advancements
3.2.1.3. Rising point-of-care (POC) hematological tests
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulations
3.2.2.2. High cost of product
3.3. Hematology Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. HEMATOLOGY DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Hematology Testing Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Instrument
4.4.1.1. Instrument Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Analyzers
4.4.1.2.1. Analyzers Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Flow cytometers
4.4.1.3.1. Flow cytometers Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Others
4.4.1.4.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Consumables
4.4.2.1. Consumables Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Reagents
4.4.2.2.1. Reagents Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Strains
4.4.2.3.1. Strains Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. HEMATOLOGY DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
5.1. Test type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Hematology Testing Market by Test type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Blood count
5.4.1.1. Blood count Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Platelet function
5.4.2.1. Platelet function Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hemoglobin
5.4.3.1. Hemoglobin Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Hematocrit
5.4.4.1. Hematocrit Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. HEMATOLOGY DIAGNOSTICS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Hematology Testing Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals
6.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic labs
6.4.2.1. Diagnostic labs Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. HEMATOLOGY DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. North America
7.5.2. U.S.
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Canada
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. Europe
7.6.2. UK
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Germany
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. France
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Italy
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Spain
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Norway
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive scenario
7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Sweden
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework
7.6.8.3. Competitive scenario
7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.9. Denmark
7.6.9.1. Key country dynamics
7.6.9.2. Regulatory framework
7.6.9.3. Competitive scenario
7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. China
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. India
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. Australia
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.7. Thailand
7.7.7.1. Key country dynamics
7.7.7.2. Regulatory framework
7.7.7.3. Competitive scenario
7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Latin America
7.8.2. Brazil
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. MEA
7.9.2. South Africa
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework
7.9.2.3. Competitive scenario
7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework
7.9.3.3. Competitive scenario
7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. UAE
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework
7.9.4.3. Competitive scenario
7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key country dynamics
7.9.5.2. Regulatory framework
7.9.5.3. Competitive scenario
7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Abbott
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Beckman coulter Inc,
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sysmex Corporation
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. F. Hoffman-La Roche Ltd.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Siemens Healthineers
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Nihon Kohden Corporation
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Bio-Rad laboratories
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Horiba Medical
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. EKF Diagnostics
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
